Loading...
Loading...
Also known as: HGH Frag 176-191, AOD-9604 analog
Modified growth hormone fragment focused purely on lipolysis without GH receptor activation.
Benefits
6
Conditions
4
Evidence
Preclinical studies, limited human data+ studies
Source
Synthetic hGH fragment (amino acids 176-191)
Gabriel Brain Score
Moderate
Modified growth hormone fragment focused purely on lipolysis without GH receptor activation.
C-terminal fragment of hGH targeting beta-3 adrenergic receptors on adipocytes, stimulates lipolysis and inhibits lipogenesis, no GH receptor binding (no IGF-1 elevation or glucose effects), preferentially mobilizes stubborn fat deposits.
* Dosing should be individualized. Always consult with a qualified healthcare practitioner.
Preclinical studies, limited human data
Preclinical evidence for lipolysis. Human trials show good safety but mixed efficacy results for weight loss. Mechanisms well-understood but clinical validation limited.
Investigational triple agonist targeting GIP, GLP-1, and glucagon receptors for maximal metabolic benefit and weight loss.
Dual GIP and GLP-1 receptor agonist that produces superior weight loss and glycemic control compared to GLP-1 agonists alone.
Long-acting GLP-1 receptor agonist that reduces appetite, improves glycemic control, and promotes significant weight loss.